The New Drug Development Paradigms (NEWDIGS) initiative is pleased to announce that it was recently awarded a Community Impact grant from the Danaher Foundation to support its ongoing innovation efforts … Read More
A practical approach for defining outcomes and thresholds for predictive healthcare algorithm development using real-world dataOut
As the healthcare system evolves towards value-based care, predictive algorithms can play a critical role, but their findings must be perceived as meaningful, substantial, and actionable by those outside the … Read More
Meet Marcelien Callenbach, FoCUS visiting research fellow
At NEWDIGS we welcome the opportunity to be part of rising innovation leaders’ careers, so this spring we’re excited to welcome Marcelien Callenbach, MS as a visiting scholar. While at … Read More
Medicaid best price reforms to enable innovative payment models for cell and gene therapies
Expert Review of Pharmacoeconomics & Outcomes Research, 23(2), 191–203.Quinn, C., Ciarametaro, M., Sils, B., Phares, S., & Trusheim, M. Cell and gene therapies promise durable benefits but face financial challenges … Read More
Precision Reimbursement Roundtable Proceedings
A framework to promote broader adoption of payment innovation As pharmaceutical companies launch novel products and payers strive to manage treatment costs and affordabili- ty, patient access can suffer. Payment … Read More
Health system innovation consortium NEWDIGS joins Tufts Medical Center
Media Contact: Jeremy Lechan508-333-4852jlechan@tuftsmedicalcenter.org Internationally esteemed “think and do” tank moved to the new Center for Biomedical System Design within Tufts MC’s Institute for Clinical Research and Health Policy Studies … Read More
NEWDIGS welcomes Takeda Pharmaceuticals as a new collaborator in the LEAPS Project
Takeda Pharmaceutical, a global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide, has joined the Massachusetts Institute of Technology Center for Biomedical Innovation’s New … Read More
FoCUS Monthly Recap: April 2022
RESEARCH BRIEF How can self-insured employers prepare for the portfolio impact of high-cost gene therapies coming to market? Self-insured employers currently rely on traditional stop-loss insurance to protect against unexpected … Read More
LEAPS Monthly Recap: April 2022
NEW MEMBER NEWDIGS welcomes Takeda Pharmaceuticals as a new collaborator in the LEAPS Project Takeda Pharmaceutical, a global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people … Read More
How can self-insured employers prepare for the portfolio impact of highcost gene therapies coming to market?
Self-insured employers (SIEs) currently rely on traditional stop-loss insurance to protect against unexpected high-cost claims, including those for cell and gene therapies. Given that current approvals are in rare diseases, … Read More